Literature DB >> 15013422

Improvement of DNA vaccine immunogenicity by a dual antigen expression system.

Shin Sasaki1, Fumihiko Takeshita, Tomohiro Oikawa, Yoshitsugu Kojima, Ke-Qin Xin, Kenji Okuda, Norihisa Ishii.   

Abstract

This study examined whether increased antigen expression resulted in enhanced antigen-specific immune responses in the context of DNA vaccines. To increase antigen expression, two copies of antigen expression cassettes were arranged in a plasmid pDX. BALB/c mice were intramuscularly immunized with various constructs that express influenza antigens and analysed for DNA-raised immunity. The plasmid pDX that expresses two copies of the antigen gene induced stronger antigen-specific immune responses than the plasmid pGA which expresses single antigen gene. To explore the in vivo transgene expression by pDX and pGA, luciferase activity was measured in the muscles transduced with luciferase expression plasmids. The pDX expressing two copies of luciferase induced the highest luciferase activity, which corresponded to the results from vaccination. We concluded that increasing the number of antigen expression cassettes in a vaccine construct improved antigen expression in the transduced tissue, which induced stronger DNA-raised immune responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15013422     DOI: 10.1016/j.bbrc.2003.12.204

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Alphavirus replicon approach to promoterless analysis of IRES elements.

Authors:  K I Kamrud; M Custer; J M Dudek; G Owens; K D Alterson; J S Lee; J L Groebner; J F Smith
Journal:  Virology       Date:  2006-12-06       Impact factor: 3.616

2.  DNA Vaccine Targeting Gonadotropin-Releasing Hormone Receptor and Its Application in Animal Contraception.

Authors:  Alexandre Samoylov; India Napier; Nancy Morrison; Anna Cochran; Bettina Schemera; James Wright; Russell Cattley; Tatiana Samoylova
Journal:  Mol Biotechnol       Date:  2019-02       Impact factor: 2.695

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.